Respiratory Syncitial virus infection in at risk infants and the potential impact of prophylaxis

M. Beresford, S. Clark, N. Subhedar, N. Shaw

Research output: Contribution to conferencePaper

Abstract

BACKGROUND: Bronchiolitis caused by respiratory syncytial virus (RSV) is an important cause of morbidity in ex-premature infants. In a randomised placebo controlled trial monoclonal antibody prophylaxis showed a 55% reduction in relative risk of hospital admission for these high risk infants, against a background incidence of 10.6 admissions per 100 high risk infants. AIMS: To follow a cohort of high risk infants in order to assess hospitalisation rate from RSV and the potential impact of prophylaxis for these patients in a UK local health authority. METHODS: A cohort of high risk infants from a local health authority were followed over the 1998/99 and 1999/2000 RSV seasons. The high risk population was defined as infants who, at the beginning of the seasons studied, were: (1) under 6 months old and born prior to 36 weeks gestation with no domiciliary oxygen requirement; or (2) under 24 months of age and discharged home in supplemental oxygen. All admissions with bronchiolitis during the season were identified. RESULTS: A total of 370 high risk infants were identified for the 1998/99 season and 286 for the following year. Over the two years there were 68 admissions. Significantly more admissions occurred from group 2 infants. RSV was identified in 27 cases (four admissions per hundred high risk infants). Prophylaxis may have saved up to pound 195,134 in hospital costs over the two years, but would have cost pound 1.1 million in drug acquisition costs. CONCLUSIONS: Careful consideration of risk factors is needed when selecting infants for RSV prophylaxis.
Original languageEnglish
Publication statusPublished - 2000
EventRoyal College of Paediatrics and Child Health Conference - York, United Kingdom
Duration: 25 Dec 2005 → …

Conference

ConferenceRoyal College of Paediatrics and Child Health Conference
CountryUnited Kingdom
CityYork
Period25/12/05 → …

Fingerprint

Virus Diseases
Respiratory Syncytial Viruses
Bronchiolitis
Oxygen
Drug Costs
Hospital Costs
Health
Premature Infants
Hospitalization
Randomized Controlled Trials
Monoclonal Antibodies
Placebos
Morbidity
Costs and Cost Analysis
Pregnancy
Incidence

Cite this

Beresford, M., Clark, S., Subhedar, N., & Shaw, N. (2000). Respiratory Syncitial virus infection in at risk infants and the potential impact of prophylaxis. Paper presented at Royal College of Paediatrics and Child Health Conference, York, United Kingdom.
Beresford, M. ; Clark, S. ; Subhedar, N. ; Shaw, N. / Respiratory Syncitial virus infection in at risk infants and the potential impact of prophylaxis. Paper presented at Royal College of Paediatrics and Child Health Conference, York, United Kingdom.
@conference{4cb978e24d79465999d8e8750ed1a76e,
title = "Respiratory Syncitial virus infection in at risk infants and the potential impact of prophylaxis",
abstract = "BACKGROUND: Bronchiolitis caused by respiratory syncytial virus (RSV) is an important cause of morbidity in ex-premature infants. In a randomised placebo controlled trial monoclonal antibody prophylaxis showed a 55{\%} reduction in relative risk of hospital admission for these high risk infants, against a background incidence of 10.6 admissions per 100 high risk infants. AIMS: To follow a cohort of high risk infants in order to assess hospitalisation rate from RSV and the potential impact of prophylaxis for these patients in a UK local health authority. METHODS: A cohort of high risk infants from a local health authority were followed over the 1998/99 and 1999/2000 RSV seasons. The high risk population was defined as infants who, at the beginning of the seasons studied, were: (1) under 6 months old and born prior to 36 weeks gestation with no domiciliary oxygen requirement; or (2) under 24 months of age and discharged home in supplemental oxygen. All admissions with bronchiolitis during the season were identified. RESULTS: A total of 370 high risk infants were identified for the 1998/99 season and 286 for the following year. Over the two years there were 68 admissions. Significantly more admissions occurred from group 2 infants. RSV was identified in 27 cases (four admissions per hundred high risk infants). Prophylaxis may have saved up to pound 195,134 in hospital costs over the two years, but would have cost pound 1.1 million in drug acquisition costs. CONCLUSIONS: Careful consideration of risk factors is needed when selecting infants for RSV prophylaxis.",
author = "M. Beresford and S. Clark and N. Subhedar and N. Shaw",
year = "2000",
language = "English",
note = "Royal College of Paediatrics and Child Health Conference ; Conference date: 25-12-2005",

}

Beresford, M, Clark, S, Subhedar, N & Shaw, N 2000, 'Respiratory Syncitial virus infection in at risk infants and the potential impact of prophylaxis' Paper presented at Royal College of Paediatrics and Child Health Conference, York, United Kingdom, 25/12/05, .

Respiratory Syncitial virus infection in at risk infants and the potential impact of prophylaxis. / Beresford, M.; Clark, S.; Subhedar, N.; Shaw, N.

2000. Paper presented at Royal College of Paediatrics and Child Health Conference, York, United Kingdom.

Research output: Contribution to conferencePaper

TY - CONF

T1 - Respiratory Syncitial virus infection in at risk infants and the potential impact of prophylaxis

AU - Beresford, M.

AU - Clark, S.

AU - Subhedar, N.

AU - Shaw, N.

PY - 2000

Y1 - 2000

N2 - BACKGROUND: Bronchiolitis caused by respiratory syncytial virus (RSV) is an important cause of morbidity in ex-premature infants. In a randomised placebo controlled trial monoclonal antibody prophylaxis showed a 55% reduction in relative risk of hospital admission for these high risk infants, against a background incidence of 10.6 admissions per 100 high risk infants. AIMS: To follow a cohort of high risk infants in order to assess hospitalisation rate from RSV and the potential impact of prophylaxis for these patients in a UK local health authority. METHODS: A cohort of high risk infants from a local health authority were followed over the 1998/99 and 1999/2000 RSV seasons. The high risk population was defined as infants who, at the beginning of the seasons studied, were: (1) under 6 months old and born prior to 36 weeks gestation with no domiciliary oxygen requirement; or (2) under 24 months of age and discharged home in supplemental oxygen. All admissions with bronchiolitis during the season were identified. RESULTS: A total of 370 high risk infants were identified for the 1998/99 season and 286 for the following year. Over the two years there were 68 admissions. Significantly more admissions occurred from group 2 infants. RSV was identified in 27 cases (four admissions per hundred high risk infants). Prophylaxis may have saved up to pound 195,134 in hospital costs over the two years, but would have cost pound 1.1 million in drug acquisition costs. CONCLUSIONS: Careful consideration of risk factors is needed when selecting infants for RSV prophylaxis.

AB - BACKGROUND: Bronchiolitis caused by respiratory syncytial virus (RSV) is an important cause of morbidity in ex-premature infants. In a randomised placebo controlled trial monoclonal antibody prophylaxis showed a 55% reduction in relative risk of hospital admission for these high risk infants, against a background incidence of 10.6 admissions per 100 high risk infants. AIMS: To follow a cohort of high risk infants in order to assess hospitalisation rate from RSV and the potential impact of prophylaxis for these patients in a UK local health authority. METHODS: A cohort of high risk infants from a local health authority were followed over the 1998/99 and 1999/2000 RSV seasons. The high risk population was defined as infants who, at the beginning of the seasons studied, were: (1) under 6 months old and born prior to 36 weeks gestation with no domiciliary oxygen requirement; or (2) under 24 months of age and discharged home in supplemental oxygen. All admissions with bronchiolitis during the season were identified. RESULTS: A total of 370 high risk infants were identified for the 1998/99 season and 286 for the following year. Over the two years there were 68 admissions. Significantly more admissions occurred from group 2 infants. RSV was identified in 27 cases (four admissions per hundred high risk infants). Prophylaxis may have saved up to pound 195,134 in hospital costs over the two years, but would have cost pound 1.1 million in drug acquisition costs. CONCLUSIONS: Careful consideration of risk factors is needed when selecting infants for RSV prophylaxis.

M3 - Paper

ER -

Beresford M, Clark S, Subhedar N, Shaw N. Respiratory Syncitial virus infection in at risk infants and the potential impact of prophylaxis. 2000. Paper presented at Royal College of Paediatrics and Child Health Conference, York, United Kingdom.